Ney Carter Borges: Pulse Pressure as an Integrated Marker of Arterial Stiffness and Cardiovascular Risk
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
”Pulse Pressure as an Integrated Marker of Arterial Stiffness and Cardiovascular Risk
Pulse pressure (PP), defined as the difference between systolic and diastolic blood pressure, has emerged as a clinically meaningful biomarker that extends beyond traditional blood pressure parameters.
Rather than being a simple arithmetic derivative, PP reflects the interplay between arterial stiffness, vascular compliance, and left ventricular ejection dynamics, making it a powerful integrator of cardiovascular physiology.
Evidence from landmark studies consistently demonstrates its prognostic value. In the Framingham Heart Study, each 10 mmHg increase in PP was associated with a significant rise in coronary heart disease risk, independent of mean arterial pressure.
Similarly, observational cohorts and meta-analyses have confirmed that elevated PP is strongly associated with cardiovascular mortality, stroke, and heart failure, particularly in aging populations where arterial stiffening predominates.
Mechanistically, increased PP reflects reduced elasticity of large arteries, leading to earlier wave reflection and amplification of systolic pressure. This results in increased myocardial oxygen demand, impaired coronary perfusion during diastole, and progressive endothelial dysfunction.
Over time, these effects contribute to atherosclerotic progression and target-organ damage, including renal and cerebral injury.
From an evidence-based perspective, several consistent patterns emerge. First, elevated PP is a robust marker of arterial stiffness, a central driver of cardiovascular risk. Second, each 10 mmHg increment in PP is associated with an approximate 10–25% increase in cardiovascular risk, depending on the population studied.
Third, PP shows strong and independent associations with major clinical outcomes, including coronary artery disease, stroke, heart failure, and all-cause mortality. Notably, in older hypertensive patients, PP may outperform mean arterial pressure as a predictor of adverse events.
Importantly, PP demonstrates a nonlinear (J-shaped) relationship with outcomes. While high PP (>60 mmHg) reflects vascular aging and increased pulsatile load, very low PP (<30 mmHg) may indicate reduced stroke volume or advanced cardiac dysfunction, particularly in heart failure or shock states.
Clinically, PP provides incremental value in risk stratification when interpreted alongside systolic and diastolic pressures. It serves as a functional marker of vascular aging and subclinical organ damage, offering practical insight into patient prognosis.”
Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025